GLP-1 hair shedding and 'Ozempic face': what's the drug and what's the weight loss

What the labels count

Hair loss appears in the most-common side effects listed on both the Wegovy and Zepbound labels, and each gives numbers from its weight-loss trials ^{1 2}:

Two details stand out. First, both labels use the same words: hair loss adverse reactions were associated with weight reduction ^{1 2}. Second, the risk is concentrated in women, a pattern that runs through every row of the table. The effect is rarely serious enough to stop treatment: no Zepbound-treated patient in the main trials stopped for hair loss, and on Wegovy 7.2 mg one person stopped permanently and five had their dose reduced ^{2 1}. The higher dose of semaglutide, which produces more weight loss, came with more hair loss, consistent with the link to weight reduction ¹.

Can you compare the drugs?

It is tempting to read the table as saying Zepbound causes more hair loss than Wegovy, or the reverse. Both labels warn against exactly that: they say adverse reaction rates from one drug's trials cannot be directly compared with rates from another drug's trials, because trials run under widely varying conditions ^{1 2}. The trials enrolled different people, recorded side effects in different ways and produced different amounts of weight loss. What can be said is that within each drug's own trials, hair loss was several times more common than on placebo, and higher doses with more weight loss came with more hair loss ¹.

Why women report it more

Every figure on both labels shows hair loss reported far more often by women than men: 7.1% against 0.5% on Zepbound, and 8.4% against 0.2% on the highest Wegovy dose ^{2 1}. The same pattern appears after weight-loss surgery, where female sex independently predicted shedding ³. Several explanations are plausible and none is proven: women more often have low iron stores, may notice and report thinning of longer hair more readily, and are more prone to telogen effluvium after other triggers such as childbirth. For women already experiencing hair thinning, for example around menopause, it is worth raising before starting treatment so that iron and other causes can be checked first.

Why weight loss makes hair shed: telogen effluvium

Each hair follicle cycles through a long growing phase and a short resting phase, after which the hair falls out and a new one starts. Normally only a small share of follicles rest at any time. A physical shock, such as surgery, a severe illness, childbirth or rapid weight loss with a sudden drop in food intake, can push many follicles into the resting phase at once. A few months later they shed together. Dermatologists call this telogen effluvium. It thins hair across the whole scalp rather than in patches, and it usually recovers once the trigger passes, although regrowth takes months to show.

The timeline is well documented after bariatric surgery, the closest comparison to drug-induced weight loss. In a 2026 study of 261 patients after two types of weight-loss surgery, hair loss on a standard pull test rose significantly at three months, peaked there, and improved by six; low iron was the strongest predictor of shedding, along with female sex ³. The authors describe it as a temporary and reversible complication when nutrition is monitored and supplemented ³. GLP-1 drugs produce slower weight loss than surgery, but the same mechanism, a rapid fall in calories and protein, is plausible.

Is it the drug or the weight loss?

That is the hardest question, and the honest answer is that the evidence leans towards weight loss without ruling out a direct effect. In favour of weight loss: the labels explicitly link hair loss to weight reduction, rates rise with the dose that produces more weight loss, and the timing and pattern match telogen effluvium ^{1 2}. Against a simple story: an analysis of the FDA's adverse event reports found alopecia among the five most common skin reactions reported with GLP-1 drugs, and reported more often when the drugs were used for type 2 diabetes than for weight management ⁴. Spontaneous reports cannot establish cause, and people with diabetes differ in many ways, but the finding means the question is not closed.

A 2025 review proposed that GLP-1 receptors on skin cells might affect skin and fat directly ⁵, though that work is laboratory-based and has not shown an effect on human hair. No randomised trial has compared hair loss on a GLP-1 drug with the same weight loss achieved another way, which is the comparison that would settle it.

What the trial numbers cannot tell you

Trial figures have limits worth knowing. Hair loss was counted when a participant reported it or an investigator recorded it, not measured with hair counts or scalp photographs, so mild shedding may have been missed and some reports may have had other causes. The trials ran for about a year to a year and a half, so they say little about whether shedding recurs with further dose increases or after stopping and restarting. And they enrolled people with obesity or overweight with a related illness; people who are leaner, or who lose weight unusually fast, were not studied and may experience more. The figures are a fair guide to the average experience on the approved drugs at the approved doses, not a promise for any individual.

'Ozempic face'

'Ozempic face' is a popular term, not a diagnosis, for a face that looks hollow, loose or older after weight loss on these drugs. A 2025 systematic review of the plastic surgery literature found 23 articles discussing GLP-1 drugs, describing changes that resemble advanced ageing and the surgical and non-surgical options used to treat them, and noted a surge in online searches for the term ⁶. What it did not find was measured data comparing facial change on a GLP-1 drug with facial change after the same weight loss by diet or surgery.

Facial fat sits in compartments that give the face its fullness, and they shrink when body fat falls, whatever the cause. Losing 15% or 20% of body weight in a year, the size of loss these drugs produce, will change most faces, especially in older adults whose skin is less elastic. The 2025 mechanisms review argues that GLP-1 drugs might also affect fat-derived stem cells and skin fibroblasts directly ⁵, but again this has not been shown in people. For now, the evidence supports treating 'Ozempic face' as the face of significant weight loss, with a possible drug contribution unproven.

Muscle, protein and the speed of loss

Part of what people notice is the loss of muscle and other lean tissue along with fat. Weight-loss drugs reduce both, and the balance matters for strength and appearance. A body-composition analysis of retatrutide, a newer drug in trials, found roughly three parts fat lost for every one part lean tissue at 36 weeks ⁷. Protein intake and resistance exercise are the standard ways to protect lean mass during weight loss, and they are also among the things dermatologists check when hair sheds, because low protein and iron are common contributors ³.

The speed of weight loss may matter too. Rapid loss is a recognised trigger for telogen effluvium, and the bariatric data show shedding concentrated in the fastest phase of loss ³. Slower dose escalation, which the labels already require for tolerability, may also be gentler on hair, though no trial has tested that directly.

What helps

For hair, the main points are patience and checking for fixable causes. Telogen effluvium usually settles on its own once weight stabilises, and shedding that continues beyond about six months, comes in patches, or is accompanied by scalp symptoms needs a doctor or dermatologist, because other causes, from thyroid disease to pattern hair loss, can coincide. Blood tests for iron, and sometimes zinc, vitamin D and thyroid function, are common first steps, given the link between low iron and shedding after weight-loss surgery ³. Adequate protein matters. Approved treatments for pattern hair loss exist; our article on peptides for hair loss explains why peptide products are not among the proven ones.

For the face, the options described in the plastic surgery literature range from fillers to surgery ⁶. Many people find their appearance settles as weight stabilises. Anyone considering cosmetic treatment after GLP-1 weight loss should wait until their weight has been stable for a while, because further loss changes the result.

Do not stop or reduce a prescribed GLP-1 drug because of hair shedding without talking to your prescriber. The labels report that few people stop for it, and stopping usually brings the weight back.

When to see a doctor

Diffuse shedding a few months into weight loss is common and usually temporary. See a doctor or dermatologist if any of the following applies: shedding continues beyond about six months; hair falls out in patches, or the scalp is red, scaly, painful or itchy; eyebrows or body hair are affected; you also have symptoms such as tiredness, feeling cold or palpitations that could point to thyroid or iron problems; or you have lost weight much faster than expected. These features suggest a cause other than, or in addition to, telogen effluvium, and some of those causes are treatable. Bring a note of when you started the drug, each dose change and when shedding began, because the timeline is the main clue.

Compounded and research products

Everything above comes from trials of the approved drugs at known doses. People using compounded or research semaglutide, tirzepatide or retatrutide are exposed to the same weight-loss effects with less certainty about the dose they are actually getting, which can mean faster loss than intended. Our guide to compounded, branded and research tirzepatide sets out the differences, and the GLP-1 transition hub covers changing treatment safely.

Frequently asked questions

Does Ozempic cause hair loss?

Hair loss is a listed side effect of semaglutide at weight-loss doses: in Wegovy's trials it was reported by 3.3% on 2.4 mg against 1% on placebo, mostly women. The label says it was associated with weight reduction.

Does tirzepatide cause hair loss?

In Zepbound's weight-loss trials, hair loss was reported by 4% to 5% of patients against 1% on placebo, 7.1% of women and 0.5% of men. No Zepbound-treated patient stopped treatment because of it.

Is GLP-1 hair loss permanent?

The pattern fits telogen effluvium, temporary shedding that follows rapid weight loss by a few months and usually recovers. Shedding that lasts beyond about six months or comes in patches should be checked by a doctor.

What is Ozempic face?

A popular term for the hollow or older look some people develop after large weight loss on GLP-1 drugs. It is not a diagnosis, and there is little measured evidence that the drugs affect the face beyond the weight loss itself.

Related on Grey Peptides

• Semaglutide
• Tirzepatide
• GLP-1 transition hub

Sources

1. Novo Nordisk. Wegovy (semaglutide) US prescribing information, sections 6.1 (hair loss) and the adverse reaction tables (DailyMed set ee06186f, effective June 18, 2026); read in full October 3, 2026.
2. Eli Lilly. Zepbound (tirzepatide) US prescribing information, section 6.1, Table 1 and hair loss text (DailyMed set 487cd7e7, effective August 28, 2026); read in full October 3, 2026.
3. Chinisaz, F., et al. (2026). Comparative Analysis of Postoperative Hair Loss and Micronutrient Deficiencies After One-Anastomosis Gastric Bypass Versus Sleeve Gastrectomy. Obes Surg, 36(4), 1804-1813. PMID: 41894131
4. Daniel, S., et al. (2025). A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies. J Drugs Dermatol, 24(4), 413-415. PMID: 40196945
5. Paschou, I. A., et al. (2025). GLP-1RA and the possible skin aging. Endocrine, 89(3), 680-685. PMID: 40498168
6. Daneshgaran, G., et al. (2025). "Ozempic Face" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions. Aesthet Surg J Open Forum, 7, ojaf056. PMID: 40626110
7. Coskun, T., et al. (2025). Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol, 13(8), 674-684. PMID: 40609566

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.